论文部分内容阅读
目的 :观察干扰素和胸腺五肽联合应用治疗慢性乙型肝炎的临床疗效和不良反应。方法 :6 4例慢性乙型肝炎患者 ,随机分为治疗组和对照组。治疗组使用干扰素α 2b6个月和胸腺五肽 3个月 ;对照组单纯使用干扰素α 2b 6个月。结果 :治疗 6个月后 ,两组ALT复常显著。HBV DNA、HBeAg阴转率治疗组分别为 6 5 .6 3% ,6 2 .5 % ;对照组分别为 4 6 .88% ,37.5 % ,两组相比 ,HBeAg阴转率有显著性差异 (P <0 .0 5 )。停药 1年后 ,HBV DNA阴转率治疗组为 71.88% ;对照组为 4 3.75 %。HBeAg阴转率治疗组为6 2 .5 % ,对照组为 34.38% ,两组相比 ,差异显著 (P <0 .0 5 )。结论 :胸腺五肽能调节和提高受损的细胞免疫功能 ,与干扰素联合应用 ,抗病毒作用显著提高 ,并能明显抑制HBV复制。
Objective: To observe the clinical efficacy and adverse reactions of interferon combined with thymopentin in the treatment of chronic hepatitis B. Methods: Sixty-four patients with chronic hepatitis B were randomly divided into treatment group and control group. The treatment group used interferon alpha 2b for 6 months and thymopentin for 3 months; the control group received interferon alpha 2b for 6 months alone. Results: After six months of treatment, ALT normalization was significant in both groups. HBV DNA, HBeAg negative conversion rate of treatment group were 65.36%, 62.5%; control group were 46.88%, 37.5%, compared with the two groups, HBeAg negative conversion rate was significantly different (P <0. 05). After 1 year of withdrawal, the rate of HBV DNA negative conversion was 71.88% in the control group and 4. 3.75% in the control group. The HBeAg negative conversion rate was 62.5% in the treatment group and 34.38% in the control group, with significant difference between the two groups (P <0.05). Conclusion: Thymopentin can regulate and improve the damaged cellular immune function. Combined with interferon, thymopentin can significantly enhance the antiviral effect and inhibit HBV replication significantly.